Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy
Conditions
Interventions
GRT-C901
GRT-R902
+3 more
Locations
3
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
NYU Langone Health
New York, New York, United States
Christ Hospital Cancer Center
Cincinnati, Ohio, United States
Start Date
May 19, 2022
Primary Completion Date
September 1, 2022
Completion Date
September 1, 2022
Last Updated
December 31, 2024
NCT07541924
NCT06662786
NCT06663319
NCT05239741
NCT06885697
NCT05770102
Lead Sponsor
Gritstone bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions